Neoadjuvant PD-1 blockade in early-stage mismatch repair–deficient solid rectal and non-rectal tumors can eliminate the need ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

FTSE 100 top-tenner GSK PLC (LSE:GSK, NYSE:GSK) has also reported earnings ahead of expectations, and kept full year guidance ...

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...

Use of a neoadjuvant checkpoint inhibitor enabled a high proportion of patients with early-stage mismatch repair-deficient ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning they did not need to undergo surgery, radiation or chemotherapy.

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Carol Ryan is a Heard on the Street columnist based in London, where she covers European energy companies, property and the ...

Large and mid-cap vaccine makers are, as of now, unworried about their 2025 pipelines in the face of research funding ...

Dr. Ali Sherif normally gives about 50 doses of the measles vaccine to children each month at his clinic in Hobbs, New Mexico ...